Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
about
In Vivo Delivery Systems for Therapeutic Genome EditingHoming and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy?Recent advances of biomaterials in biotherapyAdvanced cell therapies: targeting, tracking and actuation of cells with magnetic particlesProgress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseasesTissue engineering tools for modulation of the immune responseTherapeutic genome editing: prospects and challengesHighly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapyMultiparameter evaluation of in vivo gene delivery using ultrasound-guided, microbubble-enhanced sonoporationThe effect of injection speed and serial injection on propidium iodide entry into cultured HeLa and primary neonatal fibroblast cells using lance array nanoinjection.Physical approaches for nucleic acid delivery to liver.Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector.Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide librariesEnabling customization of non-viral gene delivery systems for individual cell types by surface-induced mineralization.Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectorsCombining Oncolytic Virotherapy with p53 Tumor Suppressor Gene TherapyStimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factorsMultifunctional Nucleus-targeting Nanoparticles with Ultra-high Gene Transfection Efficiency for In Vivo Gene TherapymRNA vaccine delivery using lipid nanoparticles.Strategies to modulate immune responses: a new frontier for gene therapyCytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primatesGene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.Options for tracking GFP-Labeled transplanted myoblasts using in vivo fluorescence imaging: implications for tracking stem cell fateAntitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model.Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors.Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexesEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Baculovirus vector-mediated transfer of NIS gene into colon tumor cells for radionuclide therapy.Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1A promising gene delivery system developed from PEGylated MoS2 nanosheets for gene therapy."Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts.Characterization of a permissive epitope insertion site in adenovirus hexonProduction and characterization of novel recombinant adeno-associated virus replicative-form genomes: a eukaryotic source of DNA for gene transfer.Opportunities for multicomponent hybrid hydrogels in biomedical applicationsFiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.Recognition and suppression of transfected plasmids by protein ZNF511-PRAP1, a potential molecular barrier to transgene expression.Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors.
P2860
Q26748886-18AB2E20-7B81-437F-A747-A9ADDE4D76F4Q26750318-751FFB35-A482-4A2A-AC1E-2B9E558BD5B2Q26752054-D6838D6F-B144-4A35-AF33-31EFDAE26527Q26782710-42616C0B-1AAC-4514-9B2E-28F46A161D9EQ27011249-9F7A08F3-54C9-471B-BF1C-B0B11C08F701Q27023419-0646CC7B-615D-45FD-9D71-55332E39A52CQ28087380-59C996E1-C036-4133-9CE8-E81A2B86725CQ28383844-EFD88FB6-A3E0-410F-9DFD-AF7D66143851Q30363593-0948D683-D70A-4DC9-9E4C-3CAA6D7A97CAQ30378182-A302F970-5BF1-4471-855B-985C4FB61503Q30484817-2F65F352-47AD-4970-A3AC-1B4F8A2D647FQ33241058-EFB8B784-FCF4-48BA-8DB5-CF5026A5C765Q33428576-13E7741B-7E46-47D5-ADE8-50482475ED5CQ33495442-7424E321-8465-4D2B-B6B9-38C0F58916FBQ33575626-98166E7D-D69D-4B49-BE6C-3D72768ABE25Q33633277-B67C3B0B-097A-4DCC-B5E1-4F67A241C9F7Q33635355-75EE425D-BDDD-4E62-8CC4-0EFCED47BB3FQ33667160-239447EF-BFBA-47B7-8570-7210F3078E38Q33703111-D68718EA-0F67-4E27-9E95-A676581CCC94Q33711685-A7F6B046-C0FC-4696-85FE-2DA35914744DQ33713999-E8633079-683F-4BB2-9679-80105F468F80Q33792012-A78C40D4-B588-4FF0-8DDC-4F06B32BC2FCQ33822191-5B419063-AB2A-43DD-8E49-6758CF8354E1Q33881920-C1882F9A-93E6-4044-A3D5-4E60CF6594D5Q33898074-08016635-D4AB-4E43-A44A-728137431BAAQ33975595-60BA049C-CF7A-4955-8045-716EC2B6B08BQ34034500-5E692302-DEAA-40BE-98AB-3DD4FF83D74AQ34058107-1B20AB3C-231E-4FBC-8DD9-D06A4324B2FAQ34069571-A8D75CE5-F978-4CDC-ACEE-FAB7A3D0F8CCQ34306787-2485B04F-C643-42CD-AD19-6A80B9D4AAB3Q34428875-187E0E62-6270-4433-8FF8-B7CA479AFCE0Q34434903-AF25F641-79C6-44E8-B485-DC4033226801Q34435548-8DDAD2A1-AD5C-4B69-85E7-7DEC39320B49Q34450094-A2F346AE-9AE1-45A5-9672-9AA35EA077BCQ34648067-BB63C4E7-AB02-4FDC-9570-600854E3CDE5Q34924696-C9BECF33-FE97-46FA-B00A-A4ECB2F2201EQ34959739-7B14A70B-347A-469A-B72E-341606A64B66Q35139196-EAFA7A0B-F7A2-421A-8457-252FB8DC9BA0Q35144453-4E5D2F68-9BF2-4BF8-B753-1011BE68A57DQ35226125-42EDDFDA-599F-4216-915A-024039606897
P2860
Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Immune responses to gene thera ...... ction and effector mechanisms.
@ast
Immune responses to gene thera ...... ction and effector mechanisms.
@en
type
label
Immune responses to gene thera ...... ction and effector mechanisms.
@ast
Immune responses to gene thera ...... ction and effector mechanisms.
@en
prefLabel
Immune responses to gene thera ...... ction and effector mechanisms.
@ast
Immune responses to gene thera ...... ction and effector mechanisms.
@en
P2093
P2860
P356
P1433
P1476
Immune responses to gene thera ...... ction and effector mechanisms.
@en
P2093
Boissier MC
GarciaCozar FJ
P2860
P2888
P356
10.1038/SJ.GT.3302364
P478
11 Suppl 1
P577
2004-10-01T00:00:00Z
P5875
P6179
1040355762